SPRB (Spruce Biosciences) Beta: 3.9181 (As of Jul. 06, 2026)


SPRB Spruce Biosciences Inc SPRB
40 GF Score
Price $51.85
GF Value $4.08
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Spruce Biosciences Beta?

Spruce Biosciences SPRB -1.26% 40 Beta is 3.9181 as of Jul. 06, 2026. GuruFocus rates SPRB with a GF Score™ of 40/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-06), Spruce Biosciences's Beta is 3.9181.


Spruce Biosciences  (NAS:SPRB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Spruce Biosciences Beta Related Terms


Spruce Biosciences Beta Historical Data

* Premium members only.

The historical data trend for Spruce Biosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spruce Biosciences Beta Chart

Spruce Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 2.59 2.46 6.26

Spruce Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.84 3.41 6.26 4.51

SPRB vs TLSA, MIST, TNYA: Beta Comparison

For the Biotechnology subindustry, Spruce Biosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spruce Biosciences Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Beta distribution charts can be found below:

* The bar in red indicates where Spruce Biosciences's Beta falls into.


SPRB
40GF Score
Spruce Biosciences Inc SPRB
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spruce Biosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.9181 mean?
Spruce Biosciences (SPRB) has a Beta of 3.9181 as of Jul. 06, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Spruce Biosciences and its competitors.
Is Spruce Biosciences' Beta too high?
Spruce Biosciences' current Beta is 3.9181. Overall, Spruce Biosciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' Beta compare to TLSA and MIST?
Spruce Biosciences' Beta of 3.9181 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Spruce Biosciences and its competitors. Spruce Biosciences's current Beta is 3.9181. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $51.85 — trading 1170.8% above its estimated fair value. The current Beta is 3.9181. Spruce Biosciences' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current Beta is 3.9181 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spruce Biosciences (SPRB) Overvalued in 2026?

Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued. The current stock price of $51.85 is trading 1170.8% above its estimated GF Value™ of $4.08. GuruFocus considers Spruce Biosciences to be Significantly Overvalued.

Key valuation signals for SPRB:

  • Beta: 3.9181
  • GF Value™: $4.08 vs. price of $51.85 (1170.8% above fair value)
  • GF Score™: 40/100 with 1 warning sign

No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spruce Biosciences Business Description

Address 611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
40GF Score

Get the complete analysis for SPRB

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.85
Price
$4.08
GF Value